Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia
Efficacy of Optimized Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia and Identification of Intestinal Microbiota Signature
IRCCS Azienda Ospedaliero-Universitaria di Bologna
510 participants
Feb 6, 2021
OBSERVATIONAL
Conditions
Summary
Prospective, multicenter, national, observational pharmacological study on the evaluation of efficacy of appropriate monotherapy vs combination treatment for non-complicated Enterococcus faecalis (EF) bloodstream infection (BSI) and identification of gut microbiota fingerprint of patients with EF-BSI correlated to antimicrobial treatment and clinical outcome
Eligibility
Inclusion Criteria4
- Adult (≥18 years)
- Monomicrobial EF-BSI
- Receipt of ≥ 5 days of at least one in vitro active drug (ampicillin, amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin, vancomycin, teicoplanin, daptomycin and linezolid) with or without a synergistic drug (ceftriaxone, gentamycin, streptomycin), at common suggested dosages for EF-BSI in empirical or definitive therapy
- Written informed consent
Exclusion Criteria2
- Short term (within 3 days from BSI) mortality
- Other concomitant infection
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06833593